D. Boral Capital initiated coverage of Omeros (OMER) with a Buy rating and $36 price target With Narsoplimab now poised for U.S. approval, followed by Europe, Omeros is “at an inflection point,” ...

Key findings from 2024 focused on conditions like vaccine-induced immune thrombotic thrombocytopenia, immune thrombocytopenia ...

In Brazil, researchers have identified substances with analgesic, anti-inflammatory, anti-hyperalgesic (against persistent ...

Dan Bloomfield, MD, chief medical officer, Anthos, walks through promising findings demonstrating the efficacy of abelacimab, ...

TMA-001, compared overall survival in 28 TA-TMA patients treated with narsoplimab to more than 100 high-risk TA-TMA patients in an external control registry who did not receive the treatment. The ...

Omeros (OMER) announced that an independent statistical group has completed the primary statistical analysis agreed with the FDA for ...

Omeros Corporation's (OMER) stock surged 55% after positive trial results for narsoplimab, a potential treatment for stem ...

TMA-001, demonstrated clinically meaningful and statistically significant superiority in overall survival, prompting Omeros ...

TGD001 is being developed to offer patients with clotting disorders a faster, safer and more effective treatment than today’s standard of care – saving lives and reducing disability Following the ...

Researchers at 37 sites in South Korea have found patients taking clopidogrel after percutaneous coronary intervention (PCI) ...

ACTICOR BIOTECH, a clinical-stage biopharmaceutical company founded in 2013 from the work of INSERM, is developing glenzocimab, a humanized monoclonal antibody fragment (fab) targeting the GPVI ...

TUESDAY, Dec. 10, 2024 (HealthDay News) -- People with diabetes who are taking GLP-1 meds such as Ozempic or Mounjaro may be ...